Amedeo Smart

Free Medical Literature Service



Ischemic Heart Disease

  Free Subscription

Articles published in
Am Heart J
    March 2018
  1. LOOP MS, McClure LA, Levitan EB, Al-Hamdan MZ, et al
    Fine particulate matter and incident coronary heart disease in the REGARDS cohort.
    Am Heart J. 2018;197:94-102.
    >> Share

  2. SHAVADIA JS, French W, Hellkamp AS, Thomas L, et al
    Comprehensive electrocardiogram-to-device time for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: A report from the American Heart Association mission: Lifeline program.
    Am Heart J. 2018;197:9-17.
    >> Share

  3. HAYS AG, Iantorno M, Schar M, Lai S, et al
    The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo-controlled, double-blind, crossover trial.
    Am Heart J. 2018;197:85-93.
    >> Share

  4. SONG YB, Oh SK, Oh JH, Im ES, et al
    Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
    Am Heart J. 2018;197:77-84.
    >> Share

  5. EGGERS KM, Jernberg T, Lindahl B
    High-sensitivity cardiac troponin T, left ventricular function, and outcome in non-ST elevation acute coronary syndrome.
    Am Heart J. 2018;197:70-76.
    >> Share

  6. LAGEDAL R, Elfwen L, James S, Oldgren J, et al
    Design of DISCO-Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study.
    Am Heart J. 2018;197:53-61.
    >> Share

  7. WONG YTA, Kang DY, Lee JB, Rha SW, et al
    Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial.
    Am Heart J. 2018;197:35-42.
    >> Share

  8. REDFORS B, Genereux P, Witzenbichler B, Maehara A, et al
    Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
    Am Heart J. 2018;197:142-149.
    >> Share

  9. KOPIN D, Jones WS, Sherwood MW, Wojdyla DM, et al
    Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Am Heart J. 2018;197:133-141.
    >> Share

  10. HWANG D, Park KW, Lee JM, Rhee TM, et al
    Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease.
    Am Heart J. 2018;197:103-112.
    >> Share

  11. SHERWOOD MW, Lopes RD, Sun JL, Liaw D, et al
    Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial.
    Am Heart J. 2018;197:1-8.
    >> Share

    February 2018
  12. LENG WX, Yang J, Li W, Wang Y, et al
    Rationale and design of the DEAR-OLD trial: Randomized evaluation of routinely Deferred versus EARly invasive strategy in elderly patients of 75 years or OLDer with non-ST-elevation myocardial infarction.
    Am Heart J. 2018;196:65-73.
    >> Share

  13. BAGAI A, Goodman SG, Cantor WJ, Vicaut E, et al
    Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study.
    Am Heart J. 2018;196:56-64.
    >> Share

  14. GUIMARAES PO, Leonardi S, Huang Z, Wallentin L, et al
    Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
    Am Heart J. 2018;196:28-35.
    >> Share

  15. KILIC S, Fabris E, Van't Hof AWJ, Hamm CW, et al
    Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial.
    Am Heart J. 2018;196:1-8.
    >> Share

  16. DUPRE ME, Xu H, Granger BB, Lynch SM, et al
    Access to routine care and risks for 30-day readmission in patients with cardiovascular disease.
    Am Heart J. 2018;196:9-17.
    >> Share

  17. MCCARTHY CP, McEvoy JW, Januzzi JL Jr.
    Biomarkers in stable coronary artery disease.
    Am Heart J. 2018;196:82-96.
    >> Share

  18. ANYANWAGU U, Mamza J, Donnelly R, Idris I, et al
    Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
    Am Heart J. 2018;196:18-27.
    >> Share

  19. KHAZANIE P, Al-Khatib SM, Wang TY, Crowley MJ, et al
    Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs.
    Am Heart J. 2018;196:170-177.
    >> Share

  20. CROWLEY MJ, Al-Khatib SM, Wang TY, Khazanie P, et al
    How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?
    Am Heart J. 2018;196:163-169.
    >> Share

  21. VRANCKX P, Lewalter T, Valgimigli M, Tijssen JG, et al
    Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial
    Am Heart J. 2018;196:105-112.
    >> Share

    January 2018
  22. AFANA M, Gurm HS, Seth M, Frazier KM, et al
    Primary percutaneous coronary intervention at centers with and without on-site surgical support: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Am Heart J. 2018;195:99-107.
    >> Share

  23. TARANTINI G, Ueshima D, D'Amico G, Masiero G, et al
    Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis.
    Am Heart J. 2018;195:78-85.
    >> Share

  24. ISSA OM, Roberts R, Mark DB, Boineau R, et al
    Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT).
    Am Heart J. 2018;195:70-77.
    >> Share

  25. BOSSARD M, Binbraik Y, Beygui F, Pitt B, et al
    Mineralocorticoid receptor antagonists in patients with acute myocardial infarction - A systematic review and meta-analysis of randomized trials.
    Am Heart J. 2018;195:60-69.
    >> Share

  26. LIU E, Hsueh L, Kim H, Vidovich MI, et al
    Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta-analysis.
    Am Heart J. 2018;195:39-49.
    >> Share

  27. HESS PL, Kennedy K, Cowherd M, Virani SS, et al
    Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project.
    Am Heart J. 2018;195:151-152.
    >> Share

  28. VEMULAPALLI S, Holmes DR Jr, Dai D, Matsouaka R, et al
    Valve hemodynamic deterioration and cardiovascular outcomes in TAVR: A report from the STS/ACC TVT Registry.
    Am Heart J. 2018;195:1-13.
    >> Share

    December 2017
  29. ILIESCU CA, Cilingiroglu M, Giza DE, Rosales O, et al
    "Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry).
    Am Heart J. 2017;194:83-91.
    >> Share

  30. QADERDAN K, Vos GA, McAndrew T, Steg PG, et al
    Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials.
    Am Heart J. 2017;194:73-82.
    >> Share

  31. INOHARA T, Numasawa Y, Higashi T, Ueda I, et al
    Predictors of high cost after percutaneous coronary intervention: A review from Japanese multicenter registry overviewing the influence of procedural complications.
    Am Heart J. 2017;194:61-72.
    >> Share

  32. DESAI NR, Kennedy KF, Cohen DJ, Connolly T, et al
    Contemporary risk model for inhospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry(R)-Get With The Guidelines (GWTG)(R).
    Am Heart J. 2017;194:16-24.
    >> Share

  33. HIRJI SA, Stevens SR, Shaw LK, Campbell EC, et al
    Predicting risk of cardiac events among ST-segment elevation myocardial infarction patients with conservatively managed non-infarct-related artery coronary artery disease: An analysis of the Duke Databank for Cardiovascular Disease.
    Am Heart J. 2017;194:116-124.
    >> Share

  34. GO AS, Fan D, Sung SH, Inveiss AI, et al
    Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study.
    Am Heart J. 2017;194:25-38.
    >> Share

    November 2017
  35. MUSTO C, De Felice F, Rigattieri S, Chin D, et al
    Instantaneous wave-free ratio and fractional flow reserve for the assessment of nonculprit lesions during the index procedure in patients with ST-segment elevation myocardial infarction: The WAVE study.
    Am Heart J. 2017;193:63-69.
    >> Share

  36. RUSSO JJ, Goodman SG, Cantor WJ, Ko DT, et al
    Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis.
    Am Heart J. 2017;193:46-54.
    >> Share

  37. AKINTOYE E, Briasoulis A, Afonso L
    Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification.
    Am Heart J. 2017;193:95-103.
    >> Share

  38. LEE PH, Lee JY, Lee CW, Han S, et al
    Long-term outcomes of bypass grafting versus drug-eluting stenting for left main coronary artery disease: Results from the IRIS-MAIN registry.
    Am Heart J. 2017;193:76-83.
    >> Share

  39. DOROS G, Massaro JM, Kandzari DE, Waksman R, et al
    Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach.
    Am Heart J. 2017;193:35-45.
    >> Share

  40. CHIANG MH, Wu HH, Shih CJ, Chen YT, et al
    Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients.
    Am Heart J. 2017;193:1-7.
    >> Share

  41. SHADDY R, Canter C, Halnon N, Kochilas L, et al
    Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
    Am Heart J. 2017;193:23-34.
    >> Share

    October 2017
  42. WAKSMAN R, Torguson R, Spad MA, Garcia-Garcia H, et al
    The Lipid-Rich Plaque Study of vulnerable plaques and vulnerable patients: Study design and rationale.
    Am Heart J. 2017;192:98-104.
    >> Share

  43. JESSEE R, Peart E, Beineke P, Rosenberg S, et al
    Rheumatoid arthritis complicates noninvasive whole blood gene expression testing for coronary artery disease.
    Am Heart J. 2017;192:13-18.
    >> Share

  44. DEHGHANI P, Lavoie A, Lavi S, Crawford JJ, et al
    Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
    Am Heart J. 2017;192:105-112.
    >> Share

  45. ALBERT MA, Durazo EM, Slopen N, Zaslavsky AM, et al
    Cumulative psychological stress and cardiovascular disease risk in middle aged and older women: Rationale, design, and baseline characteristics.
    Am Heart J. 2017;192:1-12.
    >> Share

    September 2017
  46. WALLERT J, Held C, Madison G, Olsson EM, et al
    Temporal changes in myocardial infarction incidence rates are associated with periods of perceived psychosocial stress: A SWEDEHEART national registry study.
    Am Heart J. 2017;191:12-20.
    >> Share

  47. GUDNADOTTIR GS, Andersen K, Thrainsdottir IS, James SK, et al
    Gender differences in coronary angiography, subsequent interventions, and outcomes among patients with acute coronary syndromes.
    Am Heart J. 2017;191:65-74.
    >> Share

  48. FARB A, Zuckerman BD
    Clinical event adjudication in cardiovascular device trials: An Food and Drug Administration perspective.
    Am Heart J. 2017;191:62-64.
    >> Share

  49. REN HY, Khera A, de Lemos JA, Ayers CR, et al
    Soluble endothelial cell-selective adhesion molecule and incident cardiovascular events in a multiethnic population.
    Am Heart J. 2017;191:55-61.
    >> Share

  50. KIM Y, Soffler M, Paradise S, Jelani QU, et al
    Depression is associated with recurrent chest pain with or without coronary artery disease: A prospective cohort study in the emergency department.
    Am Heart J. 2017;191:47-54.
    >> Share

  51. WEI J, Mehta PK, Grey E, Garberich RF, et al
    Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol.
    Am Heart J. 2017;191:30-36.
    >> Share

    August 2017
  52. BAGAI A, Alexander KP, Berger JS, Senior R, et al
    Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis.
    Am Heart J. 2017;190:135-139.
    >> Share

  53. PROIETTI M, Airaksinen KEJ, Rubboli A, Schlitt A, et al
    Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry.
    Am Heart J. 2017;190:86-93.
    >> Share

  54. IVERS N, Schwalm JD, Witteman HO, Presseau J, et al
    Interventions Supporting Long-term Adherence aNd Decreasing cardiovascular events (ISLAND): Pragmatic randomized trial protocol.
    Am Heart J. 2017;190:64-75.
    >> Share

  55. PALMERINI T, Serruys P, Kappetein AP, Genereux P, et al
    Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients.
    Am Heart J. 2017;190:54-63.
    >> Share

  56. JIANG R, Babyak MA, Brummett BH, Hauser ER, et al
    Brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism is associated with disease severity and incidence of cardiovascular events in a patient cohort.
    Am Heart J. 2017;190:40-45.
    >> Share

  57. PAPENDICK C, Blyth A, Seshadri A, Edmonds MJR, et al
    A randomized trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: Design of the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T (RAPID-TnT) study.
    Am Heart J. 2017;190:25-33.
    >> Share

  58. SARA JDS, Prasad M, Zhang M, Lennon RJ, et al
    High-sensitivity C-reactive protein is an independent marker of abnormal coronary vasoreactivity in patients with non-obstructive coronary artery disease.
    Am Heart J. 2017;190:1-11.
    >> Share

  59. HAMM W, Rizas KD, Stulpnagel LV, Vdovin N, et al
    Implantable cardiac monitors in high-risk post-infarction patients with cardiac autonomic dysfunction and moderately reduced left ventricular ejection fraction: Design and rationale of the SMART-MI trial.
    Am Heart J. 2017;190:34-39.
    >> Share

    July 2017
  60. FROBERT O, Gotberg M, Angeras O, Jonasson L, et al
    Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial.
    Am Heart J. 2017;189:94-102.
    >> Share

  61. NAGARAJAN V, Fonarow GC, Ju C, Pencina M, et al
    Seasonal and circadian variations of acute myocardial infarction: Findings from the Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program.
    Am Heart J. 2017;189:85-93.
    >> Share

  62. LEWIS EF, Wang R, Punjabi N, Gottlieb DJ, et al
    Impact of continuous positive airway pressure and oxygen on health status in patients with coronary heart disease, cardiovascular risk factors, and obstructive sleep apnea: A Heart Biomarker Evaluation in Apnea Treatment (HEARTBEAT) analysis.
    Am Heart J. 2017;189:59-67.
    >> Share

  63. VEMULAPALLI S, Lippmann SJ, Krucoff M, Hernandez AF, et al
    Cardiovascular events and hospital resource utilization pre- and post-transcatheter mitral valve repair in high-surgical risk patients.
    Am Heart J. 2017;189:146-157.
    >> Share

  64. KUTYIFA V, Beck C, Brown MW, Cannom D, et al
    Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol.
    Am Heart J. 2017;189:158-166.
    >> Share

    June 2017
  65. SELKER HP, Udelson JE, Ruthazer R, D'Agostino RB, et al
    Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials.
    Am Heart J. 2017;188:18-25.
    >> Share

  66. KEDHI E, Fabris E, van der Ent M, Kennedy MW, et al
    A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial".
    Am Heart J. 2017;188:11-17.
    >> Share

  67. BABER U, Sartori S, Aquino M, Kini A, et al
    Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study.
    Am Heart J. 2017;188:73-81.
    >> Share

  68. VEDANTHAN R, Kamano JH, Lee H, Andama B, et al
    Bridging Income Generation with Group Integrated Care for cardiovascular risk reduction: Rationale and design of the BIGPIC study.
    Am Heart J. 2017;188:175-185.
    >> Share

  69. DALBY AJ, Gottlieb S, Cyr DD, Magnus Ohman E, et al
    Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization.
    Am Heart J. 2017;188:156-166.
    >> Share

  70. ABNOUSI F, Sundaram V, Yong CM, Prats J, et al
    Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
    Am Heart J. 2017;188:147-155.
    >> Share

  71. JOHANSEN ND, Biering-Sorensen T, Jensen JS, Mogelvang R, et al
    Diastolic dysfunction revisited: A new, feasible, and unambiguous echocardiographic classification predicts major cardiovascular events.
    Am Heart J. 2017;188:136-146.
    >> Share

  72. MELINA G, Angeloni E, Refice S, Monti F, et al
    Clinical SYNTAX score predicts outcomes of patients undergoing coronary artery bypass grafting.
    Am Heart J. 2017;188:118-126.
    >> Share

  73. COUTE RA, Ehrenfeld JM, Gupta DK, Terekhov MA, et al
    Electronically self-assessed functional capacity and exercise testing: A comparison of the Duke Activity Status Index and Patient-Reported Outcomes Measurement Information System tools.
    Am Heart J. 2017;188:82-86.
    >> Share

  74. WIDMER RJ, Allison TG, Lennon R, Lopez-Jimenez F, et al
    Digital health intervention during cardiac rehabilitation: A randomized controlled trial.
    Am Heart J. 2017;188:65-72.
    >> Share

  75. KIM YG, Suh JW, Sibbing D, Kastrati A, et al
    A laboratory association between hemoglobin and VerifyNow P2Y12 reaction unit: A systematic review and meta-analysis.
    Am Heart J. 2017;188:53-64.
    >> Share

  76. MOGENSEN UM, Kober L, Kristensen SL, Jhund PS, et al
    The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
    Am Heart J. 2017;188:35-41.
    >> Share

    May 2017
  77. KAWADA T
    beta-Blocker after acute myocardial infarction.
    Am Heart J. 2017;187:e1.
    >> Share

  78. BAGAI A, Peterson ED, McCoy LA, Effron MB, et al
    Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of
    Am Heart J. 2017;187:19-28.
    >> Share

  79. KONG DF, Saito S, Nakamura S, Mehran R, et al
    Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic cor
    Am Heart J. 2017;187:112-121.
    >> Share

  80. DEEDWANIA P, Acharya T, Kotak K, Fonarow GC, et al
    Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program.
    Am Heart J. 2017;187:78-87.
    >> Share

  81. PAGIDIPATI NJ, Hess CN, Clare RM, Akerblom A, et al
    An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome.
    Am Heart J. 2017;187:53-61.
    >> Share

  82. HESS CN, Clare RM, Neely ML, Tricoci P, et al
    Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.
    Am Heart J. 2017;187:194-203.
    >> Share

  83. LAVI S, Dzavik V
    Recurrent MI and stroke post-acute coronary syndrome: Which is the lesser evil?
    Am Heart J. 2017;187:191-193.
    >> Share

  84. LEMMERT ME, Oldroyd K, Barragan P, Lesiak M, et al
    Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicent
    Am Heart J. 2017;187:104-111.
    >> Share

  85. SCIAHBASI A, Rigattieri S, Sarandrea A, Cera M, et al
    Determinants of operator radiation exposure during percutaneous coronary procedures.
    Am Heart J. 2017;187:10-18.
    >> Share

  86. MENTZ RJ, Bethel MA, Gustavson S, Thompson VP, et al
    Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Am Heart J. 2017;187:1-9.
    >> Share

  87. FENDER EA, Liang JJ, Sio TT, Stulak JM, et al
    Percutaneous revascularization in patients treated with thoracic radiation for cancer.
    Am Heart J. 2017;187:98-103.
    >> Share

  88. FINESCHI M, Verna E, Mezzapelle G, Bartolini D, et al
    Assessing MICRO-vascular resistances via IMR to predict outcome in STEMI patients with multivessel disease undergoing primary PCI (AMICRO): Rationale and design of a prospective multicenter clinical trial.
    Am Heart J. 2017;187:37-44.
    >> Share

  89. LANDRAY MJ, Reveal Collaborative Group
    Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitmen
    Am Heart J. 2017;187:182-190.
    >> Share

    April 2017
  90. SMITS PC, Assaf A, Richardt G, Omerovic E, et al
    Design and rationale of the COMPARE-ACUTE trial: Fractional flow reserve-guided primary multivessel percutaneous coronary intervention to improve guideline indexed actual standard of care for treatment of ST-elevation myocardial infarction in patients
    Am Heart J. 2017;186:21-28.
    >> Share

  91. QINTAR M, Spertus JA, Tang Y, Buchanan DM, et al
    Noncardiac chest pain after acute myocardial infarction: Frequency and association with health status outcomes.
    Am Heart J. 2017;186:1-11.
    >> Share

  92. DUCROCQ G, Schulte PJ, Budaj A, Cornel JH, et al
    Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
    Am Heart J. 2017;186:91-99.
    >> Share

  93. SHARMA A, de Souza Brito F, Sun JL, Thomas L, et al
    Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcom
    Am Heart J. 2017;186:73-82.
    >> Share

  94. ENGBERS EM, Timmer JR, Mouden M, Knollema S, et al
    Changes in cardiovascular medication after coronary artery calcium scanning and normal single photon emission computed tomography myocardial perfusion imaging in symptomatic patients.
    Am Heart J. 2017;186:56-62.
    >> Share

  95. LEE SE, Lin FY, Lu Y, Chang HJ, et al
    Rationale and design of the Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization: Relation to Cardiovascular Outcomes, Cost Effectiveness and Quality of Life (CONSERVE) trial.
    Am Heart J. 2017;186:48-55.
    >> Share

  96. HANNAN EL, Zhong Y, Jacobs AK, Ling FSK, et al
    Incomplete revascularization for percutaneous coronary interventions: Variation among operators, and association with operator and hospital characteristics.
    Am Heart J. 2017;186:118-126.
    >> Share

    March 2017
  97. LOU B, Gao H, Zhou C
    Remote ischemic conditioning in ST-segment elevation myocardial infarction: Effect of coronary collateral circulation.
    Am Heart J. 2017;185:e1.
    >> Share

  98. NAKANISHI K, Jin Z, Homma S, Elkind MS, et al
    Left ventricular mass-geometry and silent cerebrovascular disease: The Cardiovascular Abnormalities and Brain Lesions (CABL) study.
    Am Heart J. 2017;185:85-92.
    >> Share

  99. BAVISHI C, Sardar P, Chatterjee S, Khan AR, et al
    Intravascular ultrasound-guided vs angiography-guided drug-eluting stent implantation in complex coronary lesions: Meta-analysis of randomized trials.
    Am Heart J. 2017;185:26-34.
    >> Share

  100. LEE H, Koo BK, Park KW, Shin ES, et al
    A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary arte
    Am Heart J. 2017;185:17-25.
    >> Share

  101. KHETAN A, Purushothaman R, Zullo M, Gupta R, et al
    Rationale and design of a cluster-randomized controlled trial to evaluate the effects of a community health worker-based program for cardiovascular risk factor control in India.
    Am Heart J. 2017;185:161-172.
    >> Share

  102. HUFFMAN MD, Mohanan PP, Devarajan R, Baldridge AS, et al
    Acute coronary syndrome quality improvement in Kerala (ACS QUIK): Rationale and design for a cluster-randomized stepped-wedge trial.
    Am Heart J. 2017;185:154-160.
    >> Share

  103. YUSUF S, Joseph P
    The epidemic of cardiovascular disease in South Asians: Time for action.
    Am Heart J. 2017;185:150-153.
    >> Share

  104. CHAMBERLAIN AM, Alonso A, Gersh BJ, Manemann SM, et al
    Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study.
    Am Heart J. 2017;185:74-84.
    >> Share

  105. KUPSKY DF, Ahmed AM, Sakr S, Qureshi WT, et al
    Cardiorespiratory fitness and incident heart failure: The Henry Ford ExercIse Testing (FIT) Project.
    Am Heart J. 2017;185:35-42.
    >> Share

    February 2017
  106. VARENHORST C, Johnston N
    RE: Letter to the editor, Dr Cheng et al. "Smartphone apps and secondary prevention after myocardial infarction-How can long-term usage be improved?"
    Am Heart J. 2017;184:e2.
    >> Share

  107. CHENG K, Oswal A
    Smartphone apps and secondary prevention after myocardial infarction - How can long-term usage be improved?
    Am Heart J. 2017;184:e1.
    >> Share

  108. ARMSTRONG PW, Zheng Y, Westerhout CM, Rosell-Ortiz F, et al
    Corrigendum to "Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial" [Am Heart J 169/6 (2015) 890-898].
    Am Heart J. 2017;184:157.
    >> Share

  109. WELSH RC, Roe MT, Steg PG, James S, et al
    Corrigendum to "A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease" [Am Heart J 181 (2016) 92-100].
    Am Heart J. 2017;184:156.
    >> Share

  110. NEWMAN JD, Rockman CB, Kosiborod M, Guo Y, et al
    Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease.
    Am Heart J. 2017;184:114-120.
    >> Share

  111. ERNE P, Iglesias JF, Urban P, Eberli FR, et al
    Left bundle-branch block in patients with acute myocardial infarction: Presentation, treatment, and trends in outcome from 1997 to 2016 in routine clinical practice.
    Am Heart J. 2017;184:106-113.
    >> Share

  112. VOORA D, Coles A, Lee KL, Hoffmann U, et al
    An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial.
    Am Heart J. 2017;184:133-140.
    >> Share

  113. COFFENG JK, van der Ploeg HP, Castellano JM, Fernandez-Alvira JM, et al
    A 30-month worksite-based lifestyle program to promote cardiovascular health in middle-aged bank employees: Design of the TANSNIP-PESA randomized controlled trial.
    Am Heart J. 2017;184:121-132.
    >> Share

  114. FANOLA CL, Mooney D, Cowan AJ, Ko D, et al
    Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants.
    Am Heart J. 2017;184:150-155.
    >> Share

  115. BERWANGER O, de Barros E Silva PG, Barbosa RR, Precoma DB, et al
    Atorvastatin for high-risk statin-naive patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial.
    Am Heart J. 2017;184:88-96.
    >> Share

  116. KHAN H, Jaffar N, Rauramaa R, Kurl S, et al
    Cardiorespiratory fitness and nonfatalcardiovascular events: A population-based follow-up study.
    Am Heart J. 2017;184:55-61.
    >> Share

  117. SORENSEN LL, Liang HY, Pinheiro A, Hilser A, et al
    Safety profile and utility of treadmill exercise in patients with high-gradient hypertrophic cardiomyopathy.
    Am Heart J. 2017;184:47-54.
    >> Share

  118. SENTHONG V, Wu Y, Hazen SL, Tang WH, et al
    Predicting long-term prognosis in stable peripheral artery disease with baseline functional capacity estimated by the Duke Activity Status Index.
    Am Heart J. 2017;184:17-25.
    >> Share

    January 2017
  119. SHERWOOD A, Smith PJ, Hinderliter AL, Georgiades A, et al
    Effects of exercise and stress management training on nighttime blood pressure dipping in patients with coronary heart disease: A randomized, controlled trial.
    Am Heart J. 2017;183:85-90.
    >> Share

  120. LU Y, Zhou S, Dreyer RP, Caulfield M, et al
    Sex differences in lipid profiles and treatment utilization among young adults with acute myocardial infarction: Results from the VIRGO study.
    Am Heart J. 2017;183:74-84.
    >> Share

  121. ZETTLER ME, Peterson ED, McCoy LA, Effron MB, et al
    Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events a
    Am Heart J. 2017;183:62-68.
    >> Share

  122. BOCCARA F, Miantezila Basilua J, Mary-Krause M, Lang S, et al
    Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy.
    Am Heart J. 2017;183:91-101.
    >> Share

  123. VENKATESH BA, Nauffal V, Noda C, Fujii T, et al
    Baseline assessment and comparison of arterial anatomy, hyperemic flow, and skeletal muscle perfusion in peripheral artery disease: The Cardiovascular Cell Therapy Research Network "Patients with Intermittent Claudication Injected with ALDH Bright Cel
    Am Heart J. 2017;183:24-34.
    >> Share

  124. RIMAC G, Fearon WF, De Bruyne B, Ikeno F, et al
    Clinical value of post-percutaneous coronary intervention fractional flow reserve value: A systematic review and meta-analysis.
    Am Heart J. 2017;183:1-9.
    >> Share

    December 2016
  125. AU YEUNG SL, Lin SL, Lam HS, Schooling CM, et al
    Effect of l-arginine, asymmetric dimethylarginine, and symmetric dimethylarginine on ischemic heart disease risk: A Mendelian randomization study.
    Am Heart J. 2016;182:54-61.
    >> Share

  126. RODRIGUEZ F, Lin S, Maron DJ, Knowles JW, et al
    Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines.
    Am Heart J. 2016;182:97-102.
    >> Share

  127. BABER U, Dangas G, Cohen DJ, Gibson CM, et al
    Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
    Am Heart J. 2016;182:125-134.
    >> Share

  128. GRODZINSKY A, Arnold SV, Wang TY, Sharma P, et al
    Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy.
    Am Heart J. 2016;182:111-118.
    >> Share

  129. HARRISON RW, Radhakrishnan V, Lam PS, Allocco DJ, et al
    Rationale and design of the East-West late lumen loss study: Comparison of late lumen loss between Eastern and Western drug-eluting stent study cohorts.
    Am Heart J. 2016;182:103-110.
    >> Share

  130. LEE JM, Cho DK, Hahn JY, Song YB, et al
    Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet The
    Am Heart J. 2016;182:1-8.
    >> Share

  131. LEE SE, Chang HJ, Rizvi A, Hadamitzky M, et al
    Rationale and design of the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography IMaging (PARADIGM) registry: A comprehensive exploration of plaque progression and its impact on clinical outcomes from a multicenter seri
    Am Heart J. 2016;182:72-79.
    >> Share

    November 2016
  132. YAKSH A, Kik C, Knops P, van Ettinger MJ, et al
    Early, de novo atrial fibrillation after coronary artery bypass grafting: Facts and features.
    Am Heart J. 2016;184:62-70.
    >> Share

  133. WELSH RC, Roe MT, Steg PG, James S, et al
    A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.
    Am Heart J. 2016;181:92-100.
    >> Share

  134. VEROUHIS D, Sorensson P, Gourine A, Henareh L, et al
    Effect of remote ischemic conditioning on infarct size in patients with anterior ST-elevation myocardial infarction.
    Am Heart J. 2016;181:66-73.
    >> Share

  135. PICCARO DE OLIVEIRA P, Gonzales V, Lopes RD, Schmidt MM, et al
    Serious infections among unselected patients with ST-elevation myocardial infarction treated with contemporary primary percutaneous coronary intervention.
    Am Heart J. 2016;181:52-59.
    >> Share

  136. MONDESIR FL, Brown TM, Muntner P, Durant RW, et al
    Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for Geographic and Racial Differences in Stroke (REGARDS).
    Am Heart J. 2016;181:43-51.
    >> Share

  137. RERUP SA, Bang LE, Mogensen UM, Engstrom T, et al
    The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction.
    Am Heart J. 2016;181:35-42.
    >> Share

  138. DERY JP, Mehta SR, Fisher HN, Zhang X, et al
    Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTud
    Am Heart J. 2016;181:26-34.
    >> Share

  139. WILDI K, Nelles B, Twerenbold R, Rubini Gimenez M, et al
    Safety and efficacy of the 0 h/3 h protocol for rapid rule out of myocardial infarction.
    Am Heart J. 2016;181:16-25.
    >> Share

  140. VIRANI SS, Akeroyd JM, Ramsey DJ, Chan WJ, et al
    Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act.
    Am Heart J. 2016;181:74-82.
    >> Share

  141. VALENTINO M, Al Danaf J, Panakos A, Ragupathi L, et al
    Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
    Am Heart J. 2016;181:130-136.
    >> Share

  142. FERRI LA, Morici N, Grosseto D, Tortorella G, et al
    A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    Am Heart J. 2016;181:101-106.
    >> Share

  143. PROIETTI M, Laroche C, Drozd M, Vijgen J, et al
    Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
    Am Heart J. 2016;181:83-91.
    >> Share

    October 2016
  144. WINDECKER S, Tijssen J, Giustino G, Guimaraes AH, et al
    Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    Am Heart J. 2016;184:81-87.
    >> Share

  145. AGARWAL SK, Kasula S, Almomani A, Hacioglu Y, et al
    Clinical and angiographic predictors of persistently ischemic fractional flow reserve after percutaneous revascularization.
    Am Heart J. 2016;184:10-16.
    >> Share

  146. SHAH R, Yow E, Jones WS, Kohl LP 3rd, et al
    Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: Findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial.
    Am Heart J. 2016;184:1-9.
    >> Share

  147. ALLEN JE, Knight S, McCubrey RO, Bair T, et al
    beta-blocker dosage and outcomes after acute coronary syndrome.
    Am Heart J. 2016;184:26-36.
    >> Share

  148. MCCARTHY CP, McEvoy JW
    The narrative review on morphine in acute coronary syndrome: Recognizing opioidergic cardioprotection-reply.
    Am Heart J. 2016;180:e7-8.
    >> Share

  149. RUAN X, Chiravuri S, Kaye AD
    The narrative review on morphine in acute coronary syndrome: Recognizing opioidergic cardioprotection.
    Am Heart J. 2016;180:e5-6.
    >> Share

  150. SRA S, Tan MK, Mehta SR, Fisher HN, et al
    Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy.
    Am Heart J. 2016;180:82-9.
    >> Share

  151. LEMKES JS, Janssens GN, Straaten HM, Elbers PW, et al
    Coronary angiography after cardiac arrest: Rationale and design of the COACT trial.
    Am Heart J. 2016;180:39-45.
    >> Share

  152. NGUYEN TL, Phan J, Hogan J, Hee L, et al
    Adverse diastolic remodeling after reperfused ST-elevation myocardial infarction: An important prognostic indicator.
    Am Heart J. 2016;180:117-27.
    >> Share

  153. SUMMERS MR, Menon V
    Insights from cardiac imaging after ST-elevation myocardial infarction: Will increased recognition of patients at risk translate into improved long-term outcomes?
    Am Heart J. 2016;180:113-6.
    >> Share

  154. KONTOS MC, Wang TY, Chen AY, Bates ER, et al
    The effect of high-risk ST elevation myocardial infarction transfer patients on risk-adjusted in-hospital mortality: A report from the American Heart Association Mission: Lifeline program.
    Am Heart J. 2016;180:74-81.
    >> Share

  155. GIBSON CM, Korjian S, Tricoci P, Daaboul Y, et al
    Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute
    Am Heart J. 2016;180:22-8.
    >> Share

    September 2016
  156. TROXEL AB, Asch DA, Mehta SJ, Norton L, et al
    Rationale and design of a randomized trial of automated hovering for post-myocardial infarction patients: The HeartStrong program.
    Am Heart J. 2016;179:166-74.
    >> Share

  157. MCNEELY C, Markwell S, Vassileva CM
    Readmission after inpatient percutaneous coronary intervention in the Medicare population from 2000 to 2012.
    Am Heart J. 2016;179:195-203.
    >> Share

  158. TANGUTURI VK, Wasfy JH
    Hospital readmissions after percutaneous coronary intervention aredeclining, but caution ahead is needed.
    Am Heart J. 2016;179:192-4.
    >> Share

  159. MARSO SP, McGuire DK, Zinman B, Poulter NR, et al
    Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.
    Am Heart J. 2016;179:175-83.
    >> Share

  160. CHANG M, Ahn JM, Kim N, Lee PH, et al
    Complete versus incomplete revascularization in patients with multivessel coronary artery disease treated with drug-eluting stents.
    Am Heart J. 2016;179:157-65.
    >> Share

  161. BHATNAGAR A, Bolli R, Johnstone BH, Traverse JH, et al
    Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.
    Am Heart J. 2016;179:142-50.
    >> Share

  162. HAO Y, Liu J, Liu J, Smith SC Jr, et al
    Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: A national effort to prompt quality enhancement for acute coronary syndrome.
    Am Heart J. 2016;179:107-15.
    >> Share

  163. DE WAHA A, Sandner S, von Scheidt M, Boening A, et al
    A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Inve
    Am Heart J. 2016;179:69-76.
    >> Share

    August 2016
  164. ABATE E, Hoogslag GE, Al Amri I, Debonnaire P, et al
    Time course, predictors, and prognostic implications of significant mitral regurgitation after ST-segment elevation myocardial infarction.
    Am Heart J. 2016;178:115-25.
    >> Share

  165. HARRISON RW, Simon D, Miller AL, de Lemos JA, et al
    Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2016;178:95-101.
    >> Share

  166. JOHNSTON N, Bodegard J, Jerstrom S, Akesson J, et al
    Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: A randomized study.
    Am Heart J. 2016;178:85-94.
    >> Share

  167. SUTTON NR, Li S, Thomas L, Wang TY, et al
    The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked dat
    Am Heart J. 2016;178:65-73.
    >> Share

  168. DECKER C, Garavalia L, Garavalia B, Gialde E, et al
    Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention.
    Am Heart J. 2016;178:190-7.
    >> Share

  169. ROTHBERG MB, Martinez KA
    Risky business: Personalizing the approach to percutaneous coronary intervention.
    Am Heart J. 2016;178:185-7.
    >> Share

  170. ARMAGANIJAN LV, Alexander KP, Huang Z, Tricoci P, et al
    Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
    Am Heart J. 2016;178:176-84.
    >> Share

  171. SELKER HP, Harris WS, Rackley CE, Marsh JB, et al
    Very early administration of glucose-insulin-potassium by emergency medical service for acute coronary syndromes: Biological mechanisms for benefit in the IMMEDIATE Trial.
    Am Heart J. 2016;178:168-75.
    >> Share

  172. RIDKER PM, Amarenco P, Brunell R, Glynn RJ, et al
    Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Eve
    Am Heart J. 2016;178:135-44.
    >> Share

  173. KAUL P, Ohman EM, Knight JD, Anstrom KJ, et al
    Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary
    Am Heart J. 2016;178:55-64.
    >> Share

  174. CAMARO C, Damen SA, Brouwer MA, Kedhi E, et al
    Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Am Heart J. 2016;178:37-44.
    >> Share

  175. RAO C, Du J, Li X, Li J, et al
    Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Se
    Am Heart J. 2016;178:9-18.
    >> Share

  176. AKERBLOM A, Clare RM, Lokhnygina Y, Wallentin L, et al
    Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial.
    Am Heart J. 2016;178:1-8.
    >> Share

    July 2016
  177. DOLL JA, Wang TY, Choudhry NK, Cannon CP, et al
    Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarct
    Am Heart J. 2016;177:33-41.
    >> Share

  178. TING R, Tejpal A, Finken L, Fisher M, et al
    Repatriation to referral hospital after reperfusion of STEMI patients transferred for primary percutaneous coronary intervention: Insights of a Canadian regional STEMI care system.
    Am Heart J. 2016;177:145-52.
    >> Share

  179. REN S, Hure A, Peel R, D'Este C, et al
    Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE).
    Am Heart J. 2016;177:58-65.
    >> Share

  180. DELGADO-LISTA J, Perez-Martinez P, Garcia-Rios A, Alcala-Diaz JF, et al
    CORonary Diet Intervention with Olive oil and cardiovascular PREVention study (the CORDIOPREV study): Rationale, methods, and baseline characteristics: A clinical trial comparing the efficacy of a Mediterranean diet rich in olive oil versus a low-fat
    Am Heart J. 2016;177:42-50.
    >> Share

  181. CHUN S, Choi Y, Chang Y, Cho J, et al
    Sugar-sweetened carbonated beverage consumption and coronary artery calcification in asymptomatic men and women.
    Am Heart J. 2016;177:17-24.
    >> Share

  182. NDREPEPA G, Iijima R, Kufner S, Braun S, et al
    Association of progression or regression of coronary artery atherosclerosis with long-term prognosis.
    Am Heart J. 2016;177:9-16.
    >> Share

  183. SHIMADA YJ, Bansilal S, Wiviott SD, Becker RC, et al
    Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Am Heart J. 2016;177:1-8.
    >> Share

    June 2016
  184. GRIMFJARD P, Erlinge D, Koul S, Lagerqvist B, et al
    Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb/IIIa inhibitor treatment: A nationwide Swedish registry report.
    Am Heart J. 2016;176:78-82.
    >> Share

  185. BLUMENTHAL JA, Feger BJ, Smith PJ, Watkins LL, et al
    Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial.
    Am Heart J. 2016;176:53-62.
    >> Share

  186. PATTI G, Cavallari I
    Extended duration dual antiplatelet therapy in patients with myocardial infarction: A study-level meta-analysis of controlled randomized trials.
    Am Heart J. 2016;176:36-43.
    >> Share

  187. GONZALEZ HM, Tarraf W, Rodriguez CJ, Gallo LC, et al
    Cardiovascular health among diverse Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos (HCHS/SOL) results.
    Am Heart J. 2016;176:134-44.
    >> Share

  188. JOUNI H, Askew JW, Crusan DJ, Miller TD, et al
    Temporal trends of single-photon emission computed tomography myocardial perfusion imaging in patients without prior coronary artery disease: A 22-year experience at a tertiary academic medical center.
    Am Heart J. 2016;176:127-33.
    >> Share

  189. VENTURA HO, Lavie CJ
    Tackling cardiovascular disease in Hispanic/Latinos: Achieving 2020 Goals.
    Am Heart J. 2016;176:125-6.
    >> Share

  190. MCCARTHY CP, Mullins KV, Sidhu SS, Schulman SP, et al
    The on- and off-target effects of morphine in acute coronary syndrome: A narrative review.
    Am Heart J. 2016;176:114-21.
    >> Share

  191. PURI R, Nissen SE, Somaratne R, Cho L, et al
    Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
    Am Heart J. 2016;176:83-92.
    >> Share

  192. DE LUCA L, Capranzano P, Patti G, Parodi G, et al
    Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations.
    Am Heart J. 2016;176:44-52.
    >> Share

  193. VAN DER HEIJDEN LC, Kok MM, Danse PW, Schramm AR, et al
    Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial.
    Am Heart J. 2016;176:28-35.
    >> Share

  194. LOPES RD, de Paola AA, Lorga Filho AM, Consolim-Colombo FM, et al
    Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study.
    Am Heart J. 2016;176:10-6.
    >> Share

  195. ANDERSON LL, Dai D, Miller AL, Roe MT, et al
    Percutaneous coronary intervention for older adults who present with syncope and coronary artery disease? Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2016;176:1-9.
    >> Share

    May 2016
  196. VAN DIJK PR, Mouden M, Hermanides R
    Directions for future trials on blood glucose-lowering drugs to improve left ventricular function post-ST-segment elevation myocardial infarction.
    Am Heart J. 2016;175:e1.
    >> Share

  197. XU H, Li W, Yang J, Wiviott SD, et al
    The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China.
    Am Heart J. 2016;175:193-201.
    >> Share

  198. SILVERMAN MG, Morrow DA
    Hospital triage of acute myocardial infarction: Is admission to the coronary care unit still necessary?
    Am Heart J. 2016;175:172-4.
    >> Share

  199. PILGRIM T, Vranckx P, Valgimigli M, Stefanini GG, et al
    Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction.
    Am Heart J. 2016;175:56-65.
    >> Share

  200. ERLINGE D, Koul S, Eriksson P, Schersten F, et al
    Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial).
    Am Heart J. 2016;175:36-46.
    >> Share

  201. WEBER B, Bersch-Ferreira AC, Torreglosa CR, Ross-Fernandes MB, et al
    Corrigendum to 'The Brazilian Cardioprotective Nutritional Program to reduce events and risk factors in secondary prevention for cardiovascular disease: study protocol (The BALANCE Program Trial)' [American Heart Journal 171/1 (2016) 73-81].
    Am Heart J. 2016;175:202-203.
    >> Share

  202. VAN DIEPEN S, Lin M, Bakal JA, McAlister FA, et al
    Do stable non-ST-segment elevation acute coronary syndromes require admission to coronary care units?
    Am Heart J. 2016;175:184-92.
    >> Share

  203. PARSH J, Seth M, Briguori C, Grossman P, et al
    The optimal definition of contrast-induced acute kidney injury for prediction of inpatient mortality in patients undergoing percutaneous coronary interventions.
    Am Heart J. 2016;175:160-7.
    >> Share

  204. ARBEL Y, Qiu F, Bennell MC, Austin PC, et al
    Association between publication of appropriate use criteria and the temporal trends in diagnostic angiography in stable coronary artery disease: A population-based study.
    Am Heart J. 2016;175:153-9.
    >> Share

  205. REED BN, Fox ER, Konig M, Jackevicius CA, et al
    The impact of drug shortages on patients with cardiovascular disease: causes, consequences, and a call to action.
    Am Heart J. 2016;175:130-41.
    >> Share

  206. HUISMAN J, van der Heijden LC, Kok MM, Danse PW, et al
    Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents: A patient-level pooled analysis from TWENTE and DUTCH PEERS (TWENTE II).
    Am Heart J. 2016;175:121-9.
    >> Share

  207. ALLEN NB, Lloyd-Jones D, Hwang SJ, Rasmussen-Torvik L, et al
    Genetic loci associated with ideal cardiovascular health: A meta-analysis of genome-wide association studies.
    Am Heart J. 2016;175:112-20.
    >> Share

  208. DOBSON LE, Fairbairn TA, Musa TA, Uddin A, et al
    Sex-related differences in left ventricular remodeling in severe aortic stenosis and reverse remodeling after aortic valve replacement: A cardiovascular magnetic resonance study.
    Am Heart J. 2016;175:101-11.
    >> Share

  209. SHAFIQ A, Arnold SV, Gosch K, Kureshi F, et al
    Patient and physician discordance in reporting symptoms of angina among stable coronary artery disease patients: Insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study.
    Am Heart J. 2016;175:94-100.
    >> Share

  210. SIDEBOTTOM AC, Sillah A, Miedema MD, Vock DM, et al
    Changes in cardiovascular risk factors after 5 years of implementation of a population-based program to reduce cardiovascular disease: The Heart of New Ulm Project.
    Am Heart J. 2016;175:66-76.
    >> Share

  211. SHIMADA YJ, Cannon CP, Liu Y, Wilson C, et al
    Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care
    Am Heart J. 2016;175:18-27.
    >> Share

  212. MATHEWS R, Fonarow GC, Li S, Peterson ED, et al
    Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines.
    Am Heart J. 2016;175:1-8.
    >> Share

    April 2016
  213. GARGIULO G, Costa F, Ariotti S, Biscaglia S, et al
    Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    Am Heart J. 2016;174:95-102.
    >> Share

  214. GUIMARAES PO, Sun JL, Kragholm K, Shah SH, et al
    Association of standard clinical and laboratory variables with red blood cell distribution width.
    Am Heart J. 2016;174:22-8.
    >> Share

    March 2016
  215. BRIGUORI C, Visconti G, Donahue M, De Micco F, et al
    RenalGuard system in high-risk patients for contrast-induced acute kidney injury.
    Am Heart J. 2016;173:67-76.
    >> Share

  216. VASSALLI G, Klersy C, De Servi S, Galatius S, et al
    Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trial.
    Am Heart J. 2016;173:1-7.
    >> Share

    February 2016
  217. PESARO AE, Granger CB, Lopes RD
    Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?
    Am Heart J. 2016;172:42-4.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016